|
Report No. : |
306586 |
|
Report Date : |
17.02.2015 |
IDENTIFICATION DETAILS
|
Name : |
SM PHARMA CA |
|
|
|
|
Registered Office : |
Avenida 59-A Calle 99L-20 Edifio Sajarito Sector Barrio Bolivar PO Box 5522 Maracaibi Zulia |
|
|
|
|
Country : |
Venezuela |
|
|
|
|
Date of Incorporation : |
15.07.1977 |
|
|
|
|
Legal Form : |
Capital Anónimo |
|
|
|
|
Line of Business : |
Manufacturing, Packaging, Marketing, Importation and Exportation of
Pharmaceuticals Chemicals. |
|
|
|
|
No. of Employees : |
60 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
Venezuela |
C2 |
C2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
VENEZUELA - ECONOMIC
OVERVIEW
Venezuela remains highly
dependent on oil revenues, which account for roughly 96% of export earnings,
about 45% of budget revenues, and around 12% of GDP. Fueled by high oil prices,
pre-election government spending helped spur GDP growth in 2012 to 5.6%.
Government spending, minimum wage hikes, and improved access to domestic credit
created an increase in consumption which combined with supply problems to cause
higher inflation - roughly 20% in 2012 and rising to more than 56% in 2013.
Former President Hugo CHAVEZ's efforts to increase the government's control of
the economy by nationalizing firms in the agribusiness, financial,
construction, oil, and steel sectors hurt the private investment environment,
reduced productive capacity, and slowed non-petroleum exports. In 2013,
Venezuela continued to wrestle with housing and electricity crises, and rolling
food and goods shortages, resulting from the government's unorthodox economic
policies. The budget deficit for the public sector reached 17% of GDP in 2012
and was trimmed to under 10% of GDP in 2013. The Venezuelan government has
maintained a regime of strict currency exchange controls since 2003. Venezuelan
law now sanctions a three-tiered exchange rate system, with rates based on the
government's import priorities.
|
Source
: CIA |
Company
Name and address
|
|
|
Legal Name: |
SM Pharma CA |
|
Trade Name: |
SM PHARMA |
|
RNC: |
301017070131390,00 |
|
Date Created: |
1977 |
|
Date Incorporated: |
15/07/1977 |
|
Legal Address: |
Avenida 59-A Calle 99L-20 Edifio Sajarito Sector Barrio
Bolivar PO Box 5522 Maracaibi Zulia, Venezuela |
|
Operative Address: |
Avenida 59-A Calle 99L-20 Edifio Sajarito Sector Barrio
Bolivar PO Box 5522 Maracaibi Zulia, Venezuela |
|
Telephone: |
0261-7869777 ext 215 |
|
Fax: |
0261 - 7869226 |
|
Legal Form: |
Capital Anónimo |
|
Email: |
|
|
Registered in: |
VENEZUELA |
|
Website: |
www.sm.com.ve |
|
Contact: |
Raimundo Santamarta |
|
Staff: |
60 |
|
Activity: |
Manufacturing, Packaging, Marketing, Importation and
Exportation of Pharmaceuticals Chemicals |
|
|
|
BANKS
|
|
|
Banco Central de Venezuela |
|
|
The company does not make its banking data public |
|
|
|
|
HISTORY
|
|
|
SM Pharma CA was founded in 1977 under the name
"LABORATORIOS FARMACÉUTICOS SM C.A." as a small manufacturer of OTC
products, is today one of the most important laboratories in Venezuela. |
|
|
|
|
PRINCIPAL
ACTIVITY
|
|
|
The company's main object is Manufacturing, Packaging,
Marketing, Importation and Exportation of Pharmaceuticals Chemicals,
Alcohols; as well as any lawful business activity that is related or not to
the principal object . |
|
|
Products/Services description: |
|
|
Brands: |
AMBROX,ALBEZOL,AMPIZOD,AMPLI
,ASPICOR,AZITROM,BACIDERM,BEDENA,BETACORT,BENZALCOR,BROMA SED,CARVEL,CALCIMONIO,
CLARITIC,CITRALAMINA,DESLORT,DIAZEM,DICLOFEN P,FERROLIVER,DETROX,DICLOFEN S, |
|
Sales are: |
Wholesale |
|
Clients: |
Corporacion Medimica |
|
Suppliers: |
TMCI PADOVAN SPA, Reserch Pharmaceutical Ltd |
|
Operations area: |
National and Internaional |
|
The company imports from |
USA, ITALY |
|
The company exports to |
North of Africa, East of Europe, South America and USA |
|
The subject employs |
60 employees |
|
Payments: |
regular |
|
|
|
LOCATION
|
|
|
Headquarters : |
Avenida 59-A Calle 99L-20 Edifio Sajarito Sector Barrio
Bolivar PO Box 5522 Maracaibi Zulia, Venezuela |
|
Branches: |
The company does not have branches |
|
Industry: |
Companies in this industry manufacture and process pharmaceutical
products. Major companies include Bristol-Myers Squibb, Eli Lilly, Johnson
& Johnson, Merck & Co, and Pfizer (all based in the US), as well as
AstraZeneca (UK), Bayer (Germany), GlaxoSmithKline (UK), Novartis
(Switzerland), Roche Holding (Switzerland), and Sanofi (France). |
|
|
|
GROUP STRUCTURE AND SUBSIDIARY COMPANIES
|
|
|
Listed at the stock exchange: |
N/A |
|
Capital: |
BsF. 25,000,000.00 |
|
Shareholders %: |
Santamarta Devis, Raimundo Jose 92.72 % |
|
Management: |
Santamarta Devis, Raimundo Jose |
|
Related Companies: |
No subsidiary companies |
|
|
|
FINANCIAL
INFORMATION
|
|
|
This is a private company which does not make its
financial statements public. The following information has been provided by
our private sources. |
|
|
|
|
|
Closing Financial Analysis |
2013 |
|
Company Decapitalization Process: |
NO |
|
Solvency: |
1.837 |
|
Acid: |
0.666 |
|
Return on Assets (ROA): |
(0.021) |
|
Accounts Receivable Turnover: |
174.797 |
|
Indebtedness: |
0.265 |
|
Yield: |
(0.027) |
|
Performance Factor: |
1.276 |
|
Estimated Rate Financial Contracting: |
C |
|
Financial Capacity Estimated Contract: |
3,673,575,786.80 |
|
Estimated Financial Hiring Level: |
NIVEL XXXIX |
|
|
|
LEGAL
FILINGS
|
|
|
There are no legal found for the subject |
|
|
|
|
SUMMARY
|
|
|
SM Pharma CA was founded in 1978 as a small manufacturer
of OTC products, is today one of the most important laboratories in
Venezuela. It is a laboratory
100% Venezuelan capital in Maracaibo, Venezuela, that employs over 200 people
between professionals and highly trained technical staff . |
|
|
|
|
RISK
INFORMATION
|
|
|
DEBTS |
controlled |
|
PAYMENTS |
regular |
|
CASH FLOW |
normal |
|
STATUS |
active |
|
|
|
ENTERVIEW
|
|
|
NAME |
Gabriel |
|
POSITION |
NA |
|
COMMENTS |
We contacted the company who confirmed address, clients
and imports. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.20 |
|
|
1 |
Rs.95.99 |
|
Euro |
1 |
Rs.71.00 |
INFORMATION DETAILS
|
Analysis Done by
: |
RAS |
|
|
|
|
Report Prepared
by : |
NIT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.